Global Genome Editing Market, By Technology (CRISPR, TALEN, ZFN, ANTISENSE, Other Technologies), Application (Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug Discovery and Development, Other Applications), Product and Service (Reagents and Consumables), End User (Pharmaceutical and Biopharmaceutical Industry, Biotechnology Industry, Academic Institutions, CROs, Government Research Organizations, Others), Method (Ex-Vivo, In-Vivo) – Industry Trends and Forecast to 2029.
Genome Editing Market Analysis and Size
Genome editing is a relatively new technique for changing specific DNA sequences. It has become common practice in fundamental biomedical research to examine gene function by modifying genomes using the bacterial immune system, a potent tool for genome editing. By altering human blood cells that are then injected into the body to cure various diseases such as cystic fibrosis, cancer, and AIDS, this technology is being used more and more in studying and treating human diseases.
Data Bridge Market Research analyses that the genome editing market which was USD 5.1 billion in 2021, would rocket up to USD 17.91 billion by 2029, and is expected to undergo a CAGR of 17.00% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Genome Editing Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Technology (CRISPR, TALEN, ZFN, ANTISENSE, Other Technologies), Application (Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug Discovery and Development, Other Applications), Product and Service (Reagents and Consumables, Software and Systems, Services), End User (Pharmaceutical and Biopharmaceutical Industry, Biotechnology Industry, Academic Institutions, CROs, Government Research Organizations, Others), Method (Ex-Vivo, In-Vivo)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Market Players Covered
Merck KGaA (Germany), GenScript (China), Sangamo Therapeutics (U.S.), Lonza (Switzerland), Editas Medicine (U.S.), CRISPR Therapeutics (Switzerland), Tecan Trading AG (Switzerland), Precision Biosciences (U.S.), PerkinElmer Inc. (U.S.), Cellectis S.A (France), Genome Medical, Inc. (U.S.), BioMed Central Ltd (U.K.), Aevi Genomic Medicine, Inc. (Israel), Congenica Ltd. (U.K.), Deep Genomics (Canada), Editas Medicine (U.S.), Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.) QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.)
Genome editing is a technique for precise alterations to an organism's or cell's DNA. It is used to alter any organism's genome. It uses a special kind of enzyme called an "engineered nuclease" that makes a precise cut in the genome. A specific region of the DNA is cut, and the cell automatically heals the damage. It has uses in various fields, including agriculture, biotechnology, medicines, and mutation. In the upcoming years, the prevalence of chronic and infectious diseases will probably increase, broadening the application of genome editing.
Global Genome Editing Market Dynamics
- Developments in genome editing
Recent advancements in this area have significantly improved genome editing capabilities, allowing the change of interesting gene sequences in a number of cell types and model species. Genome engineering has evolved into a potentially game-changing diagnostic tool, particularly for oncology studies. Previously, huge research organizations such as government and academic research institutions used genome engineering. The rapid advancement of gene editing technology is the main force behind this radical shift away from academics and toward clinical and diagnostic laboratories.
- Increased application areas of genomics
Application areas for genomics include drug research, agribusiness, veterinary sciences, forensics, and the identification of human genetic abnormalities. With the introduction of next-generation sequencing, the use of genomics in forensic studies has dramatically risen, in large part to products provided by Illumina (U.S.), which were created especially for the field. Earlier, DNA analysis was utilized for fingerprint profiling. Still, today, NGS aids in crime scene analysis and makes it possible to recover more information from a trace or damaged DNA sample. This will boost market growth.
- Future developments
Future developments in genomic engineering will likely involve its application in marine engineering for projects such as the creation of nutraceuticals from algae. Other potential application areas include personalized medicine and forensic sciences. When assessing fish populations, NGS can be used for DNA barcoding to identify fish larvae and eggs as well as provide a detailed description of fish communities. Testing for food safety and quality increasingly uses genomics.
The development of new drugs, as well as the identification and management of human genetic illnesses, are greatly aided by genome editing technology. NGS, DNA analysis, profiling, and genetic engineering of plants and animals require genome editing. Thus, with the growing application areas of genomics, the demand for genome editing technologies is expected to increase across the globe during the forecast period.
- High equipment costs
The cost of genomic instruments, which can range from USD 10 to 20 million, is high since they have cutting-edge features and functions. Pharmaceutical businesses and research labs spend a lot of capital buying several genomic equipment because they need many of these systems.
On the other hand, the high cost of equipment along with ethical, regulatory and scientific challenges, off-target effects of technology will obstruct the market's growth rate.
This genome editing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the genome editing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Genome Editing Market
COVID-19 had a positive impact on the genome editing market. The COVID-19 epidemic has put more strain on the world's healthcare systems. 4 927 723 deaths and 242,348,657 confirmed cases of COVID-19 have been reported by the WHO (as of October 22, 2021). The Americas had the most fatalities, followed by Southeast Asia and Europe. The COVID-19 pandemic has encouraged major pharmaceutical and biotechnology businesses to invest in vaccine R&D and players in the genome editing market. Genome editing and engineering technologies are now at the forefront due to the increase in demand for vaccines and possible antiviral medicines.
- In January 2020, New England Biolabs and ERS Genomics collaborated to create and market CRISPR gene editing tools and supplies.
- In October 2020, Biogen and Scribe Therapeutics will collaborate to create CRISPR-based genetic treatments for neurological conditions like Amyotrophic Lateral Sclerosis.
- In November 2020, Precision BioSciences, Inc. and Eli Lilly, and the firm partnered to create potential in-vivo therapies for genetic illnesses using the latter company's unique ARCUS genome editing platform.
Global Genome Editing Market Scope
The genome editing market is segmented on the basis of technology, application, product and service, method and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Other Technologies
- Cell Line Engineering
- Genetic Engineering
- Diagnostic Applications
- Drug Discovery and Development
- Other Applications
Product and Service
- Pharmaceutical and Biopharmaceutical Industry
- Biotechnology Industry
- Academic Institutions
- Government Research Organizations
Genome Editing Market Regional Analysis/Insights
The genome editing market is analysed and market size insights and trends are provided by country, technology, application, product and service, method and end user as referenced above.
The countries covered in the genome editing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the genome editing market due to the growing adoption of advanced techniques in research institutes along with increasing occurrences of monogenic diseases.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the growing number of drug discovery and development activities along with growth of biotechnology and life sciences industry.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Genome editing Market Share Analysis
The genome editing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to genome editing market.
Some of the major players operating in the genome editing market are:
- Merck KGaA (Germany)
- GenScript (China)
- Sangamo Therapeutics (U.S.)
- Lonza (Switzerland)
- Editas Medicine (U.S.)
- CRISPR Therapeutics (Switzerland)
- Tecan Trading AG (Switzerland)
- Precision Biosciences (U.S.)
- PerkinElmer Inc. (U.S.)
- Cellectis S.A (France)
- Genome Medical, Inc. (U.S.)
- BioMed Central Ltd (U.K.)
- Aevi Genomic Medicine, Inc. (Israel)
- Congenica Ltd. (U.K.)
- Deep Genomics (Canada)
- Editas Medicine (U.S.)
- Illumina, Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- QIAGEN N.V. (Netherlands)
- Agilent Technologies, Inc. (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)